A systematic review of intravitreal bevacizumab for the treatment of diabetic macular edema
Fortin P, Mintzes B, Innes M
Record ID 32012000710
English
Authors' recommendations:
Although bevacizumab does not have an indication for treatment of diabetic macular edema, there is considerable interest in its use for this condition. This review found bevacizumab improved vision compared to laser therapy, insufficient evidence comparing bevacizumab to triamcinolone and lack of robust evidence for the long-term safety profile of bevacizumab.
There were no trials that directly compared bevacizumab with ranibizumab for the treatment of DME, although a recently published indirect comparison suggested that they may have similar efficacy.
Large, well-conducted trials are needed to provide better evidence of the effects of bevacizumab compared with other options, as well as to better define the optimal dose, timing, and duration of bevacizumab treatment in diabetic macular edema.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.cadth.ca/media/pdf/RD0028_RR_avastin_L3_e.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Macular Edema
- Antibodies, Monoclonal, Humanized
- Intravitreal Injections
Contact
Organisation Name:
Canadian Agency for Drugs and Technologies in Health
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.